A Nigerian vaccinologist, Simon Agwale, has
presented a report of an experimental vaccine for
the dreaded Ebola virus disease to a scientific
conference in France.
In a statement, Yuri Nakamoto, on behalf of the
scientific committee of the conference organised
by the Pasteur Institute, Paris, said the report was
one of the items discussed at the two-day
conference.
The International Conference Targeting Ebola had
more than 300 delegates from 42 countries in
attendance, Mr. Nakamoto said in the statement.
He said that the agenda of the conference
included 140 oral, short and posters
communications, latest developments in the
Ebola outbreak in Africa, and latest clinical
developments.
Others were latest innovations, vaccines and
drugs to combat Ebola, and prevention of Ebola
contamination and transmission, to be published
by the committee.
“Agwale, alongside Epie E. and Pushko P. of
Innovative Biotech Ltd, Keffi, Nasarawa State, and
Innovative Biotech USA Inc, made a presentation
on ‘Construction and Evaluation of a Highly
Immunogenic EBOLA Influenza VLP Vaccine
Candidate’.
“They prepared and evaluated EBOV VLPs that
included GP of EBOV Zaire strain in which VLPs
were expressed using recombinant baculovirus in
Sf9 cells.
He quoted the researchers as saying that they
had developed and evaluated an EBOV candidate
vaccine that was highly immunogenic in mice.
“Given the immediate need for an Ebola vaccine
and the efficiency, safety and adaptability of our
VLP platform technology, we are confident in
producing a high yield, high quality product using
the most cost effective methodologies available,
they said.
The researchers said that the vaccine approach
could be used for mass vaccination in Africa to
prevent EBOV infections and future epidemics of
the deadly disease.
They announced that they were also using their
platform technology to develop vaccines against
HIV, malaria and other diseases that plaque
Africa.
No comments:
Post a Comment